The Alzheimer's Association is proud to celebrate the individuals who have made significant contributions to further the vision of a world without Alzheimer's disease.


AAIC provides the Alzheimer's Association with the opportunity to present awards to some of the most prominent leaders in the field. These prestigious awards recognize the work of distinguished Alzheimer's researchers, as well as those who are just beginning their career in this vital field.

AAIC Lifetime Achievement Awards in Alzheimer's Disease Research

The AAIC Lifetime Achievement Awards recognize a senior investigator whose contributions, whether they have been in research, leadership or mentorship, have shown a lasting impact on the field and whose body of work has demonstrated a lifetime commitment towards progress against Alzheimer's and dementia.

The awards are named in honor of Henry Wisniewski, M.D., Ph.D.; Khalid Iqbal, Ph.D.; and Bengt Winblad, M.D., Ph.D.—co-founders of the Alzheimer's Association scientific conference, now known as the Alzheimer's Association International Conference (AAIC). Since its inception and first iteration they each held key leadership roles in planning and conceptualizing the conference:

Khalid Iqbal Lifetime Achievement Award in Alzheimer’s Disease Research
Awarded to: John Q. Trojanowski, M.D., Ph.D.

Dr. Trojanowski is the recipient of the Khalid Iqbal Lifetime Achievement Award in Alzheimer’s Research. He has been on the faculty of The Perelman School of Medicine at the University of Pennsylvania since 1981 where he is currently a professor of Pathology and Laboratory Medicine, director of the NIA Alzheimer’s Disease Center, director of the NINDS Morris K. Udall Parkinson’s Disease Center, co-director of the Center for Neurodegenerative Disease Research and director of the Institute on Aging. His research focuses on Alzheimer’s and Parkinson’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal degeneration (FTD) and related disorders. Dr. Trojanowski has made several discoveries of the major disease proteins in these disorders, and that aggregation and cell-to-cell spread of these disease proteins is a common mechanism underlying each of these conditions. His research has helped identify targets for potential drug therapies and treatments.

> Read the release

Bengt Winblad Lifetime Achievement Award in Alzheimer’s Disease Research
Awarded to: Jeffrey L. Cummings, M.D., Sc.D.

A world-renowned Alzheimer’s researcher and leader of clinical trials, Dr. Cummings is the founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. Cummings is a professor of Medicine in Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Cummings is the principal investigator and director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience. And he was the founding director of the UCLA Alzheimer’s Disease Research Center. His research interests include clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society.

> Read the release

Henry Wisniewski Lifetime Achievement Award in Alzheimer’s Disease Research
Awarded to: Ann C. McKee, M.D.

Dr. McKee is director of Neuropathology for VA Boston Healthcare System and Professor of Neurology and Pathology at Boston University School of Medicine. McKee is also director of the Chronic Traumatic Encephalopathy (CTE) Center and associate director of the Boston University Alzheimer’s Disease Center. She was the first scientist to report a link between motor neuron disease and CTE. Dr. McKee created the “McKee criteria” by defining the criteria on the changes in the brain for the diagnosis of CTE and establishing the novel staging system for the condition.

> Read the release

Jerome H. Stone Philanthropy Award for Alzheimer's Research

The Jerome H. Stone Philanthropy Award for Alzheimer's Research honors the legacy of Mr. Jerome Stone, a visionary who was among the first to call for investment in Alzheimer's research. Inspired by the loving memory of his late wife, Evelyn T. Stone, he took the helm of the Alzheimer's movement as the primary founder of the Alzheimer's Association.

Mr. Stone was renowned for his leadership, determination and generosity in the fight against Alzheimer’s, and for his support of research in particular. For many years, he served as the honorary chair of the Alzheimer's Association National Board of Directors. Mr. Stone passed away on January 1, 2015 at the age of 101.

This award, given in his name, honors the world's top philanthropists for advancing scientific progress toward treatment and prevention of Alzheimer's disease through their generous commitment to research.

Awarded to: Charles “Chuck” F. and Joanne Knight

Joanne Knight and her late husband, Chuck, have had an extraordinary impact on their home community of St. Louis, Missouri, and far beyond. Among the many causes they championed together was the one that would claim Chuck’s life in September 2017 – Alzheimer’s disease.

A longtime board member and former chair of the Alzheimer’s Association St. Louis Chapter, Joanne became familiar with Alzheimer’s when her mother developed dementia in the 1980s. Over many years, the couple contributed steadily and generously to the Association, including gifts made in conjunction with Emerson Electric Company, which Chuck led for nearly three decades as CEO. Their premier contribution to the advancement of Alzheimer’s disease research has been a $15 million gift to Washington University in St. Louis, which named its Alzheimer’s Disease Research Center (ADRC) in their honor.

The Knight ADRC at Washington University School of Medicine is one of 29 centers funded by the National Institute on Aging to facilitate research on Alzheimer’s disease and related disorders. The center and its clinical research arm – the Memory and Aging Project (MAP) – lead the Dominantly Inherited Alzheimer Network (DIAN) Observational Study and Trials Unit (DIAN-TU).

> Read the release

Awarded to: FBRI LLC

FBRI advances the discovery of novel therapeutic agents for the treatment of neurodegenerative diseases. By funding early-stage research in academia and the private sector, FBRI enables innovative discoveries and helps bridge the translation gap into potential therapeutics. Academic institutions worldwide receive FBRI funding for innovative research to further the field’s understanding of the basic biology of disease as well as the identification of novel therapeutic targets, biomarker development and technology development. FBRI also helps launch and guide new companies in the field and is a founding investor in several companies, including Denali Therapeutics.

To further accelerate the field, FBRI serves in leadership roles for various initiatives in the research community, including the Collaboration for Alzheimer’s Prevention. FBRI hosts small, focused workshops to explore cutting-edge questions in neurodegeneration, stimulate new ideas and foster collaboration and information sharing. In addition, FBRI runs Alzforum, an open-access news and information resource that reports the latest scientific findings and industry news.

> Read the release

Inge Grundke-Iqbal Award for Alzheimer's Research

The Inge Grundke-Iqbal Award for Alzheimer's Research is presented to the senior author of the most impactful study published in Alzheimer's research over the preceding two years (January 1, 2016 – December 31, 2017).

Only members from the International Society to Advance Alzheimer’s Research and Treatment (ISTAART) may nominate candidates.

Awarded to: Robert Tycko, Ph.D.

Dr. Robert Tycko is a senior investigator in the Laboratory of Chemical Physics, a basic research department in the National Institute of Diabetes and Digestive and Kidney Diseases on the National Institutes of Health campus in Bethesda, Maryland. He received his A.B. degree from Princeton University in 1980 and his Ph.D. in chemistry from the University of California at Berkeley in 1984. After postdoctoral research at the University of Pennsylvania, he joined AT&T Bell Laboratories in 1986, where he worked on the development of solid state nuclear magnetic resonance (ssNMR) methods and their applications in materials science and condensed matter physics. In 1994, Dr. Tycko moved to the NIH to establish a research program in biomolecular ssNMR.

Dr. Tycko received the American Physical Society's Earle K. Plyler Prize for Molecular Spectroscopy in 2005 and the Christian B. Anfinsen Award of the Protein Society in 2014. He is a fellow of the American Academy of Arts and Sciences, the American Physical Society and the American Association for the Advancement of Science. He is currently President of the International Society of Magnetic Resonance.

> Read the release

About Dr. Inge Grundke-Iqbal

Inge Grundke-Iqbal served as Professor and Head of Neuroimmunology at the New York State Institute for Basic Research in Developmental Disabilities from 1977 until her passing in September 2012. She was a world renowned neuroscientist and Alzheimer disease researcher. She was author/co-author of over 250 scientific publications in prestigious American and international journals and books. Dr. Grundke-Iqbal made several seminal discoveries in the biology of Alzheimer's disease and related conditions. Her discovery of the abnormal hyperphosphorylation of tau opened a whole new area of research in neurodegeneration, especially Alzheimer's disease and related tauopathies. Her research contributions won her several U.S. Public Health Service, National Institutes of Health and non-federal research grants and honors. Dr. Grundke-Iqbal served as a member of the International Scientific Advisory Committee of the International Conference on Alzheimer's Disease and Related Disorders (now known as the Alzheimer's Association International Conference).

de Leon Prizes in Neuroimaging

The de Leon Prizes in Neuroimaging recognize a senior scientist and a new investigator (first authors) who are judged to have each published the best paper in any peer-reviewed journal related to the topic of in-vivo neuroimaging of a neurodegenerative process. Members of the ISTAART Neuroimaging Professional Interest Area (NPIA) are the nominating body for the two awards.

Senior Scientist Recipient: Kejal Kantarci, M.D., M.S.

Dr. Kantarci, M.D., M.S., is a consultant and professor of radiology at the division of neuroradiology at Mayo Clinic and director of the neuroimaging core of the Mayo Clinic Alzheimer’s Disease Research Center. Her research focuses on using the advanced brain imaging technology for early diagnosis of dementia in her patients. Currently, Dr. Kantarci is leading an NIH-funded multi-center program on determining the long term effects of early menopausal hormone therapy on Alzheimer’s disease risk. She is also leading the NIH-funded Mayo Clinic Consortium on Longitudinal Imaging Biomarkers of Dementia with Lewy Bodies.

> Read the release

New Investigator Award: David T. Jones, M.D.

Dr. Jones is a senior associate consultant in the department of neurology at Mayo Clinic and an associate professor of neurology and radiology at the Mayo Clinic College of Medicine and Science. Dr. Jones’ clinical interests are in cognitive and behavioral neurology. His research focuses on developing methods to derive measurements of brain connectivity and to evaluate their potential as biomarkers in healthy aging and diseases like Alzheimer’s and other dementias. Jones studies brain networks by the mapping regions of the brain to show how information is exchanged and how that differs in people with Alzheimer’s disease.

> Read the release

Alzheimer's Imaging Consortium (AIC) Best Oral and Poster Presentations

Using review scores as a guide, the AIC Chairs judge and select the best oral and poster presentations presented during AIC. The 2018 recipients will be announced onsite during AIC 2018.

AAIC Student and Post-Doc Poster Competitions

Competitions are held in each conference program theme to determine the best posters by students and post-docs at AAIC. Judging will take place onsite by the Scientific Program Committee and invited guest judges. The competition is based on the four programmatic themes of AAIC: Basic and Translational Science, Diagnosis and Prognosis, Public Health and Psychosocial, and Therapeutics. Students and post-docs may submit their interest in the poster competition during abstract submission.


Basic and Translational Science Theme Recipient: Youbin Kim, Seoul National University

Poster: Identification of Tau Receptor Tau-Rn for Neuronal Uptake and Propagation of Oligomeric Tau

Diagnosis and Prognosis Theme Recipient: Sophie Lefevre-Arbogast, University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219

Poster: Early Blood Lipid Signature Predicting Accelerated Cognitive Decline in Older Persons

Public Health and Psychosocial Theme Recipient: Max Reason, University of North Carolina; Carolina Population Center

Poster: Bridging Life Course Socioeconomic Status and Memory: The Role of Inflammation

Therapeutics Theme Recipient: Alicia Quihuis, University of Southern California

Poster: Nanoparticle TGF-β Signaling Blockade in Trem2+ Peripheral Macrophages Attenuates Alzheimer Pathology in TgF344-AD Rats


Basic and Translational Science Theme Recipient: Charisse Winston, University of California, San Diego

Poster: Exosomes Derived from Neuronally – Induced Pluripotent Stem Cells (NiPSCEs) Propagate Human Tau in the Mouse Brain

Diagnosis and Prognosis Theme Recipient: Nicolas Barthélemy, Washington University

Poster: Mass Spectrometry Based Measurement of Longitudinal CSF Tau Identifies Different Phosphorylated Sites That Track Distinct Stages of Presymptomatic Dominantly Inherited AD

Public Health and Psychosocial Theme Recipient: Shannon Halloway, Rush University College of Nursing

Poster: The Interactive Effects of Changes in Physical Activity and Cognitive Activity on Global Cognition in Older Adults without Mild Cognitive Impairment or Dementia

Therapeutics Theme Recipient: Yun Jeong Hong, Asan Medical Center, Dong-A University College of Medicine, Biomedical Research Institute

Poster: A Multicenter, Randomized, Open-Label, Prospective Trial to Evaluate the Safety of Donepezil Hydrochloride 23 Mg with or without Intermediate Dose Titration in Patients with Alzheimer’s Disease Taking Donepezil Hydrochloride 10 Mg: Odesa Study

Emerging Concepts Series

Don't miss this innovative aspect of the AAIC program highlighting basic dementia science.

Learn More

Join the Conversation #AAIC18






> 1200px
> 992px
> 768px
< 767px